A case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab

Basit Öğe Kaydı
dc.contributor.authorPasa, Semir
dc.contributor.authorAltintas, Abdullah
dc.contributor.authorCil, Timucin
dc.contributor.authorDanis, Ramazan
dc.contributor.authorAyyildiz, Orhan
dc.contributor.authorMuftuoglu, Ekrem
dc.date.accessioned2024-04-24T16:02:20Z
dc.date.available2024-04-24T16:02:20Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description.abstractCurrent treatment options of essential mixed cryoglobulinemia (EMC); include immunosuppressive approaches, such as corticosteroids, cyclophosphamide, plasma exchange, other cytotoxic drugs in moderate to severe manifestations. Some controlled studies have been carried out to assess the efficacy of anti-CD20 monoclonal antibody, rituximab in patients with hepatitis C (HCV) related cryoglobulinemia (CG) and in patients with autoimmune disorders. Recent trials and some case reports demonstrate a beneficial role for rituximab in HCV related mixed CG. Although, the published evidence for treatment of EMC with rituximab is restricted to case reports, which have shown positive results. Several diseases include lymphoproliferative and myeloproliferative disorders, solid tumors, immunological disorders, cardiovascular disorders and some drugs associated with acquired von Willebrand disease (avWD). CG, which is a kind of immune complex disease, may be related with development of autoantibodies to various autoantigens. In this present case report, we showed the efficacy of rituximab in a 21-year-old female patient, suffered from neuropathy and arthralgia related with EMC, and developed avWD, presented with mucosal bleeding associated with CG. von Willebrand factor activity of our patient also increased with controlling the underlying disease, EMC by rituximab. This case demonstrate that rituximab may be an effective treatment option in EMC and avWD mainly related to CG.en_US
dc.identifier.doi10.1007/s11239-008-0195-0
dc.identifier.endpage222en_US
dc.identifier.issn0929-5305
dc.identifier.issn1573-742X
dc.identifier.issue2en_US
dc.identifier.pmid18193394
dc.identifier.scopus2-s2.0-62149115252
dc.identifier.scopusqualityQ1
dc.identifier.startpage220en_US
dc.identifier.urihttps://doi.org/10.1007/s11239-008-0195-0
dc.identifier.urihttps://hdl.handle.net/11468/14753
dc.identifier.volume27en_US
dc.identifier.wosWOS:000263877400017
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Thrombosis and Thrombolysis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEssential Mixed Cryoglobulinemiaen_US
dc.subjectAcquired Von Willebrand Diseaseen_US
dc.subjectRituximaben_US
dc.titleA case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximaben_US
dc.titleA case of essential mixed cryoglobulinemia and associated acquired von-Willebrand disease treated with rituximab
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu